BN Business News
Add your company to Business Communicator →

Business · 20/11/20261 min read

Novo's Sogroya® receives FDA approval as the first and only once-weekly, long-acting growth hormone for children with Turner Syndrome (TS)

EDITORIAL ILLUSTRATIONBBusinessBN
Illustration generated by Business News; it is not a source photograph.

Summary

Sogroya® is a once-weekly treatment option for appropriate children 2.5 and older, offering an alternative to once-daily therapy, which may help address the common challenge of non-adherence associated with daily injections1 Approval based on results from the pivotal REAL8 clinical trial...

Original source language: PR Newswire — Global News ReleasesOpen original release →

Explore insights

Business insights →